Literature DB >> 4006044

Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.

T Tsuruo, H Kawabata, N Nagumo, H Iida, Y Kitatani, S Tsukagoshi, Y Sakurai.   

Abstract

The calcium channel blockers verapamil, diltiazem, nicardipine, and niludipine potentiated the antitumor activities of mitotic poison antitumor agents, such as vincristine, vinblastine, vindesine, VP16-213, and taxol in P388 leukemia cells resistant to vincristine. The potentiating effect was generally dependent on the extent of cross-resistance seen in the cell line for these drugs. Calcium channel blockers also potentiate the antitumor activities of several DNA-interacting drugs, such as adriamycin, THP-adriamycin, daunomycin, aclacinomycin A, mitomycin C, actinomycin D, mitoxantrone, and nogalamycin derivatives in P388 leukemia resistant to adriamycin. Greater potentiation was observed for those antitumor agents to which the ADM-resistant cell line had become markedly cross-resistant, with the exception of the nogalamycin derivatives. Only a two-fold enhancement was observed for mitomycin C and aclacinomycin, as the cell line was only weakly cross-resistant to these agents. These results suggest the potential for therapeutic gain through the use of calcium channel blockers in combination with classic chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006044     DOI: 10.1007/bf00257287

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

2.  Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.

Authors:  H E Skipper; F M Schabel; H H Lloyd
Journal:  Semin Hematol       Date:  1978-07       Impact factor: 3.851

3.  Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells.

Authors:  T Skovsgaard
Journal:  Cancer Res       Date:  1978-12       Impact factor: 12.701

4.  [Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].

Authors:  S Akazawa; T Honda; K Sampi; K Futatsuki
Journal:  Gan To Kagaku Ryoho       Date:  1984-04

5.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Authors:  M Inaba; H Kobayashi; Y Sakurai; R K Johnson
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

6.  Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.

Authors:  G L Neil; S L Kuentzel; J P McGovren
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

7.  Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.

Authors:  L M Slater; S L Murray; M W Wetzel; R M Wisdom; E M DuVall
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

Review 9.  Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.

Authors:  T Tsuruo
Journal:  Cancer Treat Rep       Date:  1983-10

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  15 in total

1.  Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2).

Authors:  A R Alexanian; N S Arutyunian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Enhancement of etoposide-induced cytotoxicity by cyclosporin A.

Authors:  R Osieka; S Seeber; R Pannenbäcker; D Soll; P Glatte; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.

Authors:  E M Gibby; O Boyse; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Expression of verapamil hypersensitivity in multidrug-resistant cells grown as multicellular spheroids.

Authors:  M Anderson; J R Warr
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl.

Authors:  A Reymann; G Looft; C Woermann; M Dietel; R Erttmann
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Dominant expression of multidrug resistance in intraspecific murine lymphoma hybrid cells.

Authors:  I Pályi; G Turi; L Hullán; K Szikla; M Bak
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Authors:  J Soudon; M Berlion; C Lucas; P Haddad; J P Bizzari; F Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.